biotech / news / / KFF Health News
FDA approves a new medicine from Denali Therapeutics for a condition called Hunter syndrome.
The FDA approved Denali Therapeutics' enzyme replacement therapy for Hunter syndrome, not a gene therapy.
KEY POINTS
- Denali's drug can enter the brain and slow cognitive decline in two-thirds of Hunter syndrome patients.
- Merck is acquiring Terns Pharmaceuticals and its experimental leukemia drug in a nearly $6 billion cash deal.
- Non-physician clinicians now write 40% of antipsychotic prescriptions for older adults in Medicare.
COMPANIES
Summarized by Newsio from KFF Health News. How we summarize →